Clinical outcomes and predictors in patients with previous cardiac surgery undergoing mitral valve transcatheter edge-to-edge repair.
MV-TEER
MitraClip
mitral regurgitation
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
09
05
2022
received:
04
03
2022
accepted:
14
05
2022
pubmed:
2
6
2022
medline:
14
9
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Mitral-valve transcatheter edge-to-edge repair (MV-TEER) is recommended in patients with severe functional mitral regurgitation (FMR) and in those with degenerative mitral regurgitation (DMR) not eligible to traditional surgery. Patients with a history of previous cardiac surgery are considered at high risk for surgical reintervention, but data are lacking regarding procedural and clinical outcomes. aim of this study was to assess the efficacy and clinical results of MV-TEER in patients with previous cardiac surgery enrolled in the "multicentre Italian Society of Interventional Cardiology registry of transcatheter treatment of mitral valve regurgitation" (GIOTTO). Patients with previous coronary artery bypass grafting (CABG), surgical aortic valve replacement (AVR), or mitral valve repair (MVR) were included. Those with multiple or combined previous cardiac surgeries were excluded. Clinical follow-up was performed at 30 days, 1 year, and 2 years. The primary endpoint was a composite of death or rehospitalization at 1- and 2-year follow-ups. A total of 330 patients enrolled in the GIOTTO registry were considered (CABG 77.9%, AVR 14.2%, and MVR 7.9%). Most patients showed FMR (66.9%), moderate reduction of left ventricular (LV) ejection fraction, and signs of LV dilation. Procedural and device successes were 94.8% and 97%. At 1 and 2 years, the composite endpoint occurred are 29.1% and 52.4%, respectively. The composite outcome rates were similar across the three subgroups of previous cardiac surgery (p = 0.928) and between the FMR and DMR subgroups (p = 0.850) at 2 years. In a multivariate analysis, residual mitral regurgitation (rMR) ≥2+ was the main predictor of adverse events at 1 year (hazard ratio: 1.54 [95% confidence interval, CI: 1.00-2.38]; p = 0.050). This association was confirmed at 2 years of Kaplan-Meier analysis (p = 0.001). MV-TEER is effective in these patients, regardless of the subtype of previous cardiac surgery and the MR etiology. An rMR ≥2+ is independently associated with adverse outcomes at 1-year follow-up.
Sections du résumé
BACKGROUND
Mitral-valve transcatheter edge-to-edge repair (MV-TEER) is recommended in patients with severe functional mitral regurgitation (FMR) and in those with degenerative mitral regurgitation (DMR) not eligible to traditional surgery. Patients with a history of previous cardiac surgery are considered at high risk for surgical reintervention, but data are lacking regarding procedural and clinical outcomes.
OBJECTIVE
aim of this study was to assess the efficacy and clinical results of MV-TEER in patients with previous cardiac surgery enrolled in the "multicentre Italian Society of Interventional Cardiology registry of transcatheter treatment of mitral valve regurgitation" (GIOTTO).
METHODS
Patients with previous coronary artery bypass grafting (CABG), surgical aortic valve replacement (AVR), or mitral valve repair (MVR) were included. Those with multiple or combined previous cardiac surgeries were excluded. Clinical follow-up was performed at 30 days, 1 year, and 2 years. The primary endpoint was a composite of death or rehospitalization at 1- and 2-year follow-ups.
RESULTS
A total of 330 patients enrolled in the GIOTTO registry were considered (CABG 77.9%, AVR 14.2%, and MVR 7.9%). Most patients showed FMR (66.9%), moderate reduction of left ventricular (LV) ejection fraction, and signs of LV dilation. Procedural and device successes were 94.8% and 97%. At 1 and 2 years, the composite endpoint occurred are 29.1% and 52.4%, respectively. The composite outcome rates were similar across the three subgroups of previous cardiac surgery (p = 0.928) and between the FMR and DMR subgroups (p = 0.850) at 2 years. In a multivariate analysis, residual mitral regurgitation (rMR) ≥2+ was the main predictor of adverse events at 1 year (hazard ratio: 1.54 [95% confidence interval, CI: 1.00-2.38]; p = 0.050). This association was confirmed at 2 years of Kaplan-Meier analysis (p = 0.001).
CONCLUSIONS
MV-TEER is effective in these patients, regardless of the subtype of previous cardiac surgery and the MR etiology. An rMR ≥2+ is independently associated with adverse outcomes at 1-year follow-up.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-460Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Obadia J-F, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379(24):2297-2306. doi:10.1056/NEJMoa1805374
Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379(24):2307-2318. doi:10.1056/NEJMoa1806640
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. Published online. 2021;43:561-632. doi:10.1093/eurheartj/ehab395
Giordano A, Biondi-Zoccai G, Finizio F, et al. Characteristics and outcomes of MitraClip in octogenarians: evidence from 1853 patients in the GIOTTO registry. Int J Cardiol. 2021;342:65-71. doi:10.1016/j.ijcard.2021.08.010
Roques F, Nashef SAM, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardio-Thoracic Surg. 1999;15(6):816-823. doi:10.1016/S1010-7940(99)00106-2
Mehaffey HJ, Hawkins RB, Schubert S, et al. Contemporary outcomes in reoperative mitral valve surgery. Heart. 2018;104(8):652-656. doi:10.1136/heartjnl-2017-312047
Bedogni F, Testa L, Rubbio AP, et al. Real-world safety and efficacy of transcatheter mitral valve repair with MitraClip: thirty-day results from the Italian Society of Interventional Cardiology (GIse) registry of transcatheter treatment of mitral valve regurgitation (GIOTTO). Cardiovasc Revasc Med. 2020;21(9):1057-1062. doi:10.1016/j.carrev.2020.01.002
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303-371. doi:10.1016/j.echo.2017.01.007
Stone GW, Adams DH, Abraham WT, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the Mitral Valve Academic Research Consortium. J Am Coll Cardiol. 2015;66(3):308-321. doi:10.1016/j.jacc.2015.05.049
Bedogni F, Popolo Rubbio A, Grasso C, et al. Italian Society of Interventional Cardiology (GIse) registry of transcatheter treatment of mitral valve regurgitation (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation. Eur J Heart Fail. 2021;23(8):1364-1376. doi:10.1002/ejhf.2159
Pibarot P, Delgado V, Bax JJ. MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results. Eur Heart J Cardiovasc Imaging. 2019;20(6):620-624. doi:10.1093/ehjci/jez073
Adamo M, Grasso C, Capodanno D, et al. Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: insights from the multicenter GRASP-IT registry. Am Heart J. 2019;217:32-41. doi:10.1016/j.ahj.2019.06.015
Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol. 2014;64(9):875-884. doi:10.1016/j.jacc.2014.06.1166
Sürder D, Klersy C, Corti R, et al. Impact of mitral regurgitation aetiology on MitraClip outcomes: the MitraSwiss registry. EuroInterventio. 2020;16(2):e112-e120. doi:10.4244/EIJ-D-19-00718
Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052-1061. doi:10.1016/j.jacc.2013.02.094
Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol. 2017;70(19):2315-2327. doi:10.1016/j.jacc.2017.09.015
Geyer M, Keller K, Born S, et al. Predictors of short- and long-term outcomes of patients undergoing transcatheter mitral valve edge-to-edge repair. Catheter Cardiovasc Interv. 2021;97(3):E390-E401. doi:10.1002/ccd.29068
Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail. 2019;21(12):1619-1627. doi:10.1002/ejhf.1616
Puls M, Lubos E, Boekstegers P, et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J. 2016;37(8):703-712. doi:10.1093/eurheartj/ehv627
Sürder D, Pedrazzini G, Gaemperli O, et al. Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry. Heart. 2013;99(14):1034-1040. doi:10.1136/heartjnl-2012-303105
Toggweiler S, Zuber M, Sürder D, et al. Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome. Open Hear. 2014;1(1):e000056. doi:10.1136/openhrt-2014-000056
Kar S, Mack MJ, Lindenfeld J, et al. Relationship between residual mitral regurgitation and clinical and quality-of-life outcomes after transcatheter and medical treatments in heart failure: COAPT trial. Circulation. 2021;144(6):426-437. doi:10.1161/CIRCULATIONAHA.120.053061
Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64(2):182-192. doi:10.1016/j.jacc.2013.10.021
Buzzatti N, De Bonis M, Denti P, et al. What is a “good” result after transcatheter mitral repair? Impact of 2+ residual mitral regurgitation. J Thorac Cardiovasc Surg. 2016;151(1):88-96. doi:10.1016/j.jtcvs.2015.09.099
Buzzatti N, Denti P, Scarfò IS, et al. Mid-term outcomes (up to 5 years) of percutaneous edge-to-edge mitral repair in the real-world according to regurgitation mechanism: a single-center experience. Catheter Cardiovasc Interv. 2019;94(3):427-435. doi:10.1002/ccd.28029
Reichart D, Kalbacher D, Rübsamen N, et al. The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation. Eur J Heart Fail. 2020;22(10):1840-1848. doi:10.1002/ejhf.1774.
Orban M, Orban M, Lesevic H, et al. Predictors for long-term survival after transcatheter edge-to-edge mitral valve repair. J Interv Cardiol. 2017;30(3):226-233. doi:10.1111/joic.12376
Adamo M, Cani DS, Gavazzoni M, et al. Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. EuroIntervention. 2020;16(5):413-420. doi:10.4244/EIJ-D-19-01114
Higuchi S, Orban M, Stolz L, et al. Impact of residual mitral regurgitation on survival after transcatheter edge-to-edge repair for secondary mitral regurgitation. JACC Cardiovasc Interv. 2021;14(11):1243-1253. doi:10.1016/j.jcin.2021.03.050
Adamo M, Pagnesi M, Popolo Rubbio A, et al. Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation. Catheter Cardiovasc Interv. 2022;99:1626-1635. doi:10.1002/ccd.30062
Orban M, Karam N, Lubos E, et al. Impact of proportionality of secondary mitral regurgitation on outcome after transcatheter mitral valve repair. JACC Cardiovasc Imaging. 2021;14(4):715-725. doi:10.1016/j.jcmg.2020.05.042
Braun D, Frerker C, Körber MI, et al. Percutaneous edge-to-edge repair of recurrent severe mitral regurgitation after surgical mitral valve repair. J Am Coll Cardiol. 2017;70(4):504-505. doi:10.1016/j.jacc.2017.05.045
Rahhab Z, Lim DS, Little SH, et al. MitraClip after failed surgical mitral valve repair-an international multicenter study. J Am Heart Assoc. 2021;10(7):e019236. doi:10.1161/JAHA.120.019236